ZA986277B - Tumor rejection antigens presented by HLA-B44 molecules and uses thereof - Google Patents

Tumor rejection antigens presented by HLA-B44 molecules and uses thereof

Info

Publication number
ZA986277B
ZA986277B ZA986277A ZA986277A ZA986277B ZA 986277 B ZA986277 B ZA 986277B ZA 986277 A ZA986277 A ZA 986277A ZA 986277 A ZA986277 A ZA 986277A ZA 986277 B ZA986277 B ZA 986277B
Authority
ZA
South Africa
Prior art keywords
hla
molecules
tumor rejection
antigens presented
rejection antigens
Prior art date
Application number
ZA986277A
Other languages
English (en)
Inventor
Ozlem Tureci
Ugur Sahin
Michael Pfreundschuh
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of ZA986277B publication Critical patent/ZA986277B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA986277A 1997-07-15 1998-07-15 Tumor rejection antigens presented by HLA-B44 molecules and uses thereof ZA986277B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/892,702 US5888751A (en) 1997-07-15 1997-07-15 Method for diagnosis and treating cancers, and methods for identifying pathogenic markers in a sample of normal cells

Publications (1)

Publication Number Publication Date
ZA986277B true ZA986277B (en) 1999-04-15

Family

ID=25400375

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA986277A ZA986277B (en) 1997-07-15 1998-07-15 Tumor rejection antigens presented by HLA-B44 molecules and uses thereof

Country Status (11)

Country Link
US (3) US5888751A (xx)
EP (1) EP0998582A4 (xx)
JP (1) JP2001510056A (xx)
KR (1) KR100384402B1 (xx)
CN (1) CN1159453C (xx)
AU (1) AU729715B2 (xx)
CA (1) CA2295926A1 (xx)
HK (1) HK1027597A1 (xx)
NZ (1) NZ502217A (xx)
WO (1) WO1999004040A1 (xx)
ZA (1) ZA986277B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050911A2 (en) * 1997-05-02 1998-11-12 Lee Howard Hong Dough Information processing with a plurality of optical discs
US6291658B1 (en) * 1997-05-05 2001-09-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding SSX family members and thereof
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6261778B1 (en) * 1998-10-22 2001-07-17 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode SCP proteins, and uses thereof
US6214983B1 (en) * 1998-10-22 2001-04-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode SCP proteins
AU3246200A (en) * 1999-02-25 2000-09-14 Boris Bilynsky Nucleic acid molecules associated with melanoma and thyroid tumors
US6448073B1 (en) 2000-01-28 2002-09-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
WO2003000845A2 (en) * 2001-06-22 2003-01-03 Ludwig Institute For Cancer Research Methods for detection of disease-associated antibodies in urine
US6864324B2 (en) * 2002-04-19 2005-03-08 Chem First Electronic Materials L.P. Anhydrous, liquid phase process for preparing hydroxyl containing polymers of enhanced purity
KR100475449B1 (ko) * 2002-06-10 2005-03-10 (주)프로테옴텍 유방암 진단용 마커
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
AU2004249254B2 (en) * 2003-06-17 2010-07-08 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
CA2594224A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
JP5416968B2 (ja) 2005-06-17 2014-02-12 マンカインド コーポレイション 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物
US20070031876A1 (en) * 2005-08-08 2007-02-08 Hsueh-Kung Lin Methods of providing gene expression profiles for metastatic cancer phenotypes utilizing differentially expressed transcripts associated with circulating tumor cells
TW200801794A (en) * 2006-04-03 2008-01-01 Molecular Imprints Inc Method of concurrently patterning a substrate having a plurality of fields and a plurality of alignment marks
US8478545B2 (en) * 2011-06-03 2013-07-02 Agilent Technologies, Inc. Identification of aberrant microarray features
WO2012166722A1 (en) * 2011-06-03 2012-12-06 The General Hospital Corporation Treating colorectal, pancreatic, and lung cancer
WO2015085105A1 (en) * 2013-12-04 2015-06-11 University Of Alaska Fairbanks Methods and compositions for enriching non-host sequences in host samples
GB2558131B (en) 2015-09-21 2021-05-19 Surface Oncology Inc Anti-CD47 antibodies and methods of use
DE102017108254B4 (de) 2016-04-19 2019-10-02 GM Global Technology Operations LLC Rundumsichtkamerasystem zur Objekterkennung und -verfolgung und Verfahren zum Ausstatten eines Fahrzeugs mit einem Rundumsichtkamerasystem

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468481A (en) * 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5733550A (en) * 1990-05-10 1998-03-31 Dana-Farber Cancer Institute, Inc. Method for enhancing the association of exogenous peptides with class I MHC molecules on the surface of antigen presenting cells with β-microglobulin
US5824315A (en) * 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules

Also Published As

Publication number Publication date
KR100384402B1 (ko) 2003-06-27
EP0998582A1 (en) 2000-05-10
JP2001510056A (ja) 2001-07-31
US6232460B1 (en) 2001-05-15
AU729715B2 (en) 2001-02-08
AU8264998A (en) 1999-02-10
US5888751A (en) 1999-03-30
US6239256B1 (en) 2001-05-29
CN1263560A (zh) 2000-08-16
NZ502217A (en) 2001-06-29
HK1027597A1 (en) 2001-01-19
KR20010021926A (ko) 2001-03-15
CA2295926A1 (en) 1999-01-28
EP0998582A4 (en) 2004-10-13
WO1999004040A1 (en) 1999-01-28
CN1159453C (zh) 2004-07-28

Similar Documents

Publication Publication Date Title
ZA986277B (en) Tumor rejection antigens presented by HLA-B44 molecules and uses thereof
IL126811A0 (en) Human b-cell antigens and related reagents
HK1096974A1 (en) Antibody against human parathormone related peptides
ZA9810130B (en) Tumor-specific antigens methods for their production and their use for imunization and diagnosis
HUP0001971A3 (en) Soluble ctla4 mutant molecules and uses thereof
GB9927332D0 (en) Novel antibody and uses thereof
HUP0000318A3 (en) Tumor vaccine and process for the preparation thereof
ZA962280B (en) RAGE tumor rejection antigens
EP0805161A4 (en) PROTEIN BINDING (1-3) -BETA-D-GLUCANE, PROTEIN RECOGNIZING ANTIBODIES AND USE OF PROTEIN AND ANTIBODY
HUP0003674A3 (en) Functional protein concentrates and isolates
GB9520739D0 (en) HIV specific synthetic antigens and their use
EP0934749A4 (en) ARTICLE SUPPORT ELEMENT AND ARTICLE PROVIDED WITH SAME
HUP0100192A3 (en) Improved stomach-action molluscicides and preparation thereof
AU6771998A (en) Identification of the progression elevated gene-3 and uses thereof
AU2247095A (en) Cellular immune response-specific antigens and uses therefor
HUP0000523A3 (en) Carriers containing an entherlipid/complementarily shape lipid combination and therapeutic uses thereof
EP1109904A4 (en) NOVEL MOLECULES OF THE PROTEIN FAMILY ASSOCIATED WITH THE HERPES VIRUS ENTRY MEDIATOR AND THEIR APPLICATIONS
EP1009856A4 (en) MOLECULES OF A PROTEIN FAMILY RELATED TO FTHMA-070 AND THE PROTEIN FAMILY RELATED TO T85 AND THEIR USE
HUP9801330A3 (en) Novel pka-binding proteins and uses thereof
GB9423372D0 (en) Proteins and their uses
ZA986047B (en) 6-pyrrolidin-2-ylpyrindines their preparation and their therapeutic application
ZA958037B (en) Tumor rejection antigens presented by HLA-b44 molecules and uses thereof
ZA955128B (en) Novel amido-quinoxalinediones the preparation and use thereof
IL132174A0 (en) Phenoketals and the use thereof as odoriferous substances
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies